Vaccine platform Flow Pharma’s FlowVax adjuvanted microsphere peptide vaccine platform presents a potential collaboration opportunity for partners seeking accelerated vaccine development for Ebola, Marburg, COVID-19 and oncology indications.

Targeted oncology With expertise in treatment-resistant cancers and multiple oncology indications, there are sales opportunities to offer contract development, manufacturing, or licensing partnerships for novel biomedicines and delivery systems.

Strategic partnerships Recent news and funding signals indicate growth direction; engage in discussions around co-development, joint ventures, or funding-supported programs to scale manufacturing and accelerate clinical timelines.

Small team agility Sizeable revenue potential in a lean organization suggests high-value, fast-turnaround collaborations, pilot programs, and preferred vendor relationships to streamline procurement and execution.

Global biosafety focus Pipeline includes high-priority infectious disease targets (Ebola, Marburg, COVID-19) and vaccines, offering entry points for regulatory consulting, scale-up manufacturing services, and supply chain partnerships.